BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 210263)

  • 1. Myasthenia gravis: further electrophysiological and ultrastructural analysis of transmission failure in the mouse passive transfer model.
    Toyka KV; Birnberger KL; Anzil AP; Schlegel C; Besinger U; Struppler A
    J Neurol Neurosurg Psychiatry; 1978 Aug; 41(8):746-53. PubMed ID: 210263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Presynaptic function modified by acetylcholine-receptor interaction in experimental autoimmune myasthenia gravis.
    Takamori M; Sakato S; Okumura S
    J Neurol Sci; 1984; 66(2-3):245-53. PubMed ID: 6099402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Morphologic and immunopathologic findings in myasthenia gravis and in congenital myasthenic syndromes.
    Engel AG
    J Neurol Neurosurg Psychiatry; 1980 Jul; 43(7):577-89. PubMed ID: 6249893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Passive transfer of the Lambert-Eaton myasthenic syndrome: neuromuscular transmission in mice injected with plasma.
    Kim YI
    Muscle Nerve; 1985 Feb; 8(2):162-72. PubMed ID: 2997605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of myasthenic immunoglobulin G on neuromuscular transmission in mouse diaphragm.
    Chiu HC; Chen ML; Tsai MC
    Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1987 Aug; 20(3):217-23. PubMed ID: 2827968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Passively transferred myasthenia gravis: protection of mouse endplates by Fab fragments from human myasthenic IgG.
    Toyka KV; Löwenadler B; Heininger K; Besinger UA; Birnberger KL; Fateh-Moghadam A; Heilbronn E
    J Neurol Neurosurg Psychiatry; 1980 Sep; 43(9):836-42. PubMed ID: 6252294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The immunopathology of myasthenia gravis.
    Engel AG
    Int J Neurol; 1980; 14(1):35-46. PubMed ID: 6293990
    [No Abstract]   [Full Text] [Related]  

  • 8. Myasthenia gravis. Study of humoral immune mechanisms by passive transfer to mice.
    Toyka KV; Drachman DB; Griffin DE; Pestronk A; Winkelstein JA; Fishbeck KH; Kao I
    N Engl J Med; 1977 Jan; 296(3):125-31. PubMed ID: 831074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies of human myasthenia gravis: electrophysiological and ultrastructural evidence compatible with antibody attachment to acetylcholine receptor complex.
    Rash JE; Albuquerque EX; Hudson CS; Mayer RF; Satterfield JR
    Proc Natl Acad Sci U S A; 1976 Dec; 73(12):4584-8. PubMed ID: 1070009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Passive transfer of myasthenia gravis by immunoglobulins: lack of correlation between AChR with antibody bound, acetylcholine receptor loss and transmission defect.
    Mossman S; Vincent A; Newsom-Davis J
    J Neurol Sci; 1988 Mar; 84(1):15-28. PubMed ID: 2835437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuromuscular transmission in neonatal mice injected with serum globulin of myasthenia gravis patients.
    Pagala MK; Tada S; Namba T; Grob D
    Neurology; 1982 Jan; 32(1):12-7. PubMed ID: 6275304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice.
    Klooster R; Plomp JJ; Huijbers MG; Niks EH; Straasheijm KR; Detmers FJ; Hermans PW; Sleijpen K; Verrips A; Losen M; Martinez-Martinez P; De Baets MH; van der Maarel SM; Verschuuren JJ
    Brain; 2012 Apr; 135(Pt 4):1081-101. PubMed ID: 22396395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myasthenia gravis: passive transfer from man to mouse.
    Toyka KV; Brachman DB; Pestronk A; Kao I
    Science; 1975 Oct; 190(4212):397-9. PubMed ID: 1179220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pathogenesis of myasthenia gravis.
    Heilbronn E; StÄlberg E
    J Neurochem; 1978 Jul; 31(1):5-11. PubMed ID: 209148
    [No Abstract]   [Full Text] [Related]  

  • 15. An electrophysiological and morphological study of the neuromuscular junction in patients with myasthenia gravis.
    Albuquerque EX; Rash JE; Mayer RF; Satterfield JR
    Exp Neurol; 1976 Jun; 51(3):536-63. PubMed ID: 179836
    [No Abstract]   [Full Text] [Related]  

  • 16. How myasthenia gravis alters the safety factor for neuromuscular transmission.
    Ruff RL; Lennon VA
    J Neuroimmunol; 2008 Sep; 201-202():13-20. PubMed ID: 18632162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-function correlations in myasthenia gravis and a new myasthenic syndrome.
    Engel AG; Lambert EH
    Electroencephalogr Clin Neurophysiol Suppl; 1978; (34):469-77. PubMed ID: 220007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Passively transferred experimental autoimmune myasthenia gravis. Sequential and quantitative study of the motor end-plate fine structure and ultrastructural localization of immune complexes (IgG and C3), and of the acetylcholine receptor.
    Engel AG; Sakakibara H; Sahashi K; Lindstrom JM; Lambert EH; Lennon VA
    Neurology; 1979 Feb; 29(2):179-88. PubMed ID: 571062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myasthenia induced by monoclonal anti-acetylcholine receptor antibodies: clinical and electrophysiological aspects.
    Burres SA; Crayton JW; Gomez CM; Richman DP
    Ann Neurol; 1981 Jun; 9(6):563-8. PubMed ID: 6167199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunopathology of myasthenia gravis.
    Drachman DB
    Fed Proc; 1979 Nov; 38(12):2613-5. PubMed ID: 227751
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.